Big Pharma Terrifies with Its Own $100B Shadow

The Health Resources and Services Administration published a number last week, and Big Pharma's echo chamber lit up like Christmas. One hundred billion dollars. That is the amount safety-net hospitals and clinics purchased under the 340B Drug Discount Program in 2025. Up 22 percent. Hospitals accounted for 87 percent of it.

Within days, the figure was everywhere. Skyrocketing. Monstrous. One drug-industry analyst literally put a picture of Godzilla on it. Here is what none of them will tell you: That $100 billion is not money your hospital made. It is money your hospital paid. To Eli Lilly, AbbVie, and Johnson & Johnson and others. Every dollar is drug industry revenue.

And the drug companies want you outraged about it. They are holding up their own sales receipt and demanding you call it a crime scene. Why did the 340B purchase number grow?

The National Pharmaceutical Council — the drug industry's own research arm — partially funded a peer-reviewed study asking whether 340B growth comes from rising prices or from utilization. The answer, in their own data: utilization. Volume drove roughly 80 percent of 340B's growth measured at list price, and essentially all of it measured at what hospitals actually pay.

Utilization means more medicine. Reaching more patients. Through more doors.

Big Pharma commissioned a study that proved safety-net hospitals are getting more drugs to more sick people than ever. And then they published it like a rap sheet. Edad! Poor people got more medicine. Someone call the FBI!

One of the study's three authors sits on the board of directors of Kalderos — the company that invented the 340B "rebate model" back in 2020, and that today sells drug companies the very platform they want your patients' claims data funneled through. Pharma bought the research. A director of the company selling the cure helped write the diagnosis.

Nearly 90 percent of every 340B dollar buys specialty drugs. Cancer drugs. Hemophilia drugs. Multiple sclerosis drugs. The most expensive medicines on earth — priced that way by the same companies now clutching their pearls about the total spend. Big Pharma created this number. It set the price of every item on the receipt and then acts shocked at the sum.

Somehow HRSA never publishes the most important numbers of all: patients served, prescriptions written, chemotherapy infusions delivered in a county with one oncologist and no hospital for sixty miles.

Drug companies took in roughly $1.7 trillion in revenue in 2024. The entire 340B discount program comes to under five percent of that total. That’s a sliver – not an existential threat.

One hundred billion dollars is not the story of a program out of control. It is the tale of what Big Pharma charged America's safety-net hospitals in a single year, and of how much medicine those hospitals put into patients' hands.

Drug companies want you frightened of their own $100 billion shadow.